Dr. Joshua L. LaBaer, named interim executive director for the Biodesign Institute at Arizona State University.
Author Archive: AZBio
TGen study targets SGEF protein in treating glioblastoma brain tumors
Study funded by Ivy Foundation shows SGEF plays roles in how cancer cells survive and invade brain tissueContinue reading
$190 M Licensing Deal Announced with Cancer Prevention Pharmaceuticals
SUCAMPO ENTERS INTO EXCLUSIVE OPTION AND COLLABORATION AGREEMENT WITH CANCER PREVENTION PHARMACEUTICALS FOR DEVELOPMENT OF LATE-STAGE CPP-1X/SULINDAC COMBINATION FOR FAMILIAL ADENOMATOUS POLYPOSIS
Spicy Arthritis Treatment Moves to Clinical Trials
A UA research team studying the anti-inflammatory impact of turmeric is moving the project out of the laboratory and into patient testing. (Source)Continue reading
In memoriam: Peter N. Allison (1950 – 2015)
Life science entrepreneur, investor,and philanthropist Peter N. Allison passed away unexpectedly in Scottsdale, AZ on December 22, 2015.Continue reading
CTCA at Western Regional Medical Center advances combination immunotherapy clinical trial
Lung Cancer Pioneers Create Lung Cancer Eradication Pact: VisionGate Acquires Exclusive Rights to University of Colorado’s Chemoprevention Drug Iloprost
Partnership Would Combine Company’s Patented Technology that Detects Pre-cancer of the Lungs with Drug Treatment that Prevents Cancer Continue reading
Making LIFE Better: Report documents TGen’s $174 million in total annual economic impact
TGen continues to grow as an economic engine for Arizona, creating high-paying jobs, state revenues and significant return on investment. Report documents TGen’s $174 million in total annual economic impact, while also attracting research dollars and advancing precision medicineContinue reading
SenesTech Announces Management Restructuring and Changes to Board of Directors
SenesTech, Inc., an Arizona based life science company, today announced a series of significant changes and additions to its management team and board of directors. The Company believes the changes and additions to its team will help position it to commercialize its lead product candidate, ContraPest. ContraPest is an innovative technology for managing rodent pest populations through fertility as opposed to a lethal approach. SenesTech submitted ContraPest to the EPA for registration in 2015, and though there can be no assurance, the Company is hopeful of obtaining a positive determination in 2016.Continue reading
Applications open for 10th year of Helios Scholars at TGen biomedical research internships
8-week paid summer program pairs students with TGen researchers in significant efforts to benefit patientsContinue reading